Pfizer and Roche COVID Collab
Roche has launched a new clinical trial in the U.S. to help people who test negative for COVID-19 find the best resources for the best health outcomes.
Roche's Pilot COVID-19 test has added a QR code to help people get more information about COVID-19 and get more specific guidance from the CDC on testing and treatment options.
Pfizer markets two vaccines that protect against COVID: one that targets the virus itself and the other that targets those who are at high risk. Though both companies hope to promote their own products, using Roche's test to drive people to their site will, at least in part, increase the awareness and use of Pfizer's COVID products.
Roche's new test, the Pilot, is a rapid test that shows up in your saliva within 20 minutes. It is available for people aged 2 and up. Earlier in the year, the government issued a series of tests that will help people find out if they have COVID-19. The tests are free and provide an easy way for anyone to get a quick and easy result. Tests for COVID-19 are now readily accessible in the U.S., and the pharma hopes that by detecting it early, doctors can start treatment quickly.
CDC studies show that nine out of 10 Americans are having difficulty understanding and accessing personal and public health information because it contains complex terms or is confusing for some people. The goal of the collaboration is to simplify and improve access to COVID information. It was planned that the test would make it easier to find out more about COVIDs and to provide more useful information.
Tested the neocapsid protein from SARS-CoV-2 in nasal swabs. In a clinical study, the test showed that the test offered a sensitivity of 93.2% and a specificity of 100% (95% CI: 96.7% to 100%). Study used 158 samples from patients.
Roche has sold more than 1.8 billion COVID-19 tests worldwide, including laboratory-based molecule diagnostic tests and antibody tests.